FDA Extends PDUFA Date of Biohaven's Troriluzole NDA for Rare Disease Spinocerebellar Ataxia

- Spinocerebellar Ataxia (SCA) is a rare, genetic, life-threatening neurodegenerative disease with no available treatment.

- Troriluzole has been granted Fast-Track, Orphan Drug Designation (ODD) and Priority Review from the FDA.

Read more at prnewswire.com